The team independently implements trials in Japan, Korea, Taiwan, and Southeast Asia. We select sites from a range of countries in line with the particular needs of each program and we understand that many emerging pharma companies approach Asia with no thought of directly implementing trials in the region. However, throughout the process of development planning, companies often come to understand that the incremental increases in costs and complexity required to include Asian sites in global clinical trials allows companies to realize exponential growth in Asian product value. For companies that decide to independently include Asia in multinational clinical trials, our team can provide comprehensive support of clinical trial implementation throughout the region.